Tower Research Capital LLC (Trc) Praxis Precision Medicines, Inc. Transaction History

Tower Research Capital LLC (Trc)

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.83 - $1.18 $945 - $1,344	-1,139 Reduced 9.24%	11,183 $12,000
Q1 2023 May 09, 2023	SELL	$0.8 - $4.98 $11,423 - $71,109	-14,279 Reduced 53.68%	12,322 $10,000
Q4 2022 Feb 10, 2023	BUY	$1.88 - $36.45 $17,970 - $348,425	9,559 Added 56.09%	26,601 $63,000
Q3 2022 Nov 10, 2022	BUY	$2.5 - $37.95 $7,900 - $119,922	3,160 Added 22.76%	17,042 $39,000
Q2 2022 Aug 15, 2022	BUY	$1.75 - $11.34 $16,049 - $103,999	9,171 Added 194.67%	13,882 $34,000
Q1 2022 May 12, 2022	BUY	$10.21 - $20.29 $34,622 - $68,803	3,391 Added 256.89%	4,711 $48,000
Q4 2021 Feb 14, 2022	BUY	$16.76 - $22.99 $3,000 - $4,115	179 Added 15.69%	1,320 $26,000
Q3 2021 Nov 15, 2021	SELL	$13.15 - $22.56 $41,409 - $71,041	-3,149 Reduced 73.4%	1,141 $21,000
Q2 2021 Aug 16, 2021	BUY	$18.28 - $33.05 $59,391 - $107,379	3,249 Added 312.1%	4,290 $78,000
Q1 2021 May 17, 2021	BUY	$29.34 - $60.2 $19,687 - $40,394	671 Added 181.35%	1,041 $34,000
Q4 2020 Feb 16, 2021	BUY	$27.25 - $55.82 $10,082 - $20,653	370 New	370 $20,000

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.26B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.